Some of the CANMAT Recommendations for the Pharmacological Treatment of Late-life Depression Are Not Congruent with Available Evidence or Expert Opinion
- PMID: 28525727
- PMCID: PMC5459232
- DOI: 10.1177/0706743717700877
Some of the CANMAT Recommendations for the Pharmacological Treatment of Late-life Depression Are Not Congruent with Available Evidence or Expert Opinion
Conflict of interest statement
Comment in
-
Response to Letter Regarding CANMAT Recommendations for the Pharmacological Treatment of Late-life Depression.Can J Psychiatry. 2017 May;62(5):353-354. doi: 10.1177/0706743717700878. Can J Psychiatry. 2017. PMID: 28525728 Free PMC article. No abstract available.
References
-
- MacQueen GM, Frey BN, Ismail Z, et al. The CANMAT depression work group. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 6. Special populations: Youth, women, and the elderly. Can J Psychiatry. 2016;61(9):588–603. - PMC - PubMed
-
- Iqbal MM, Basil MJ, Kaplan J, et al. Overview of serotonin syndrome. Ann Clin Psychiatry. 2012;24(4):310–318. - PubMed
-
- Mulsant BH, Pollock BG. Psychopharmacology. In: Steffens DC, Blazer DG, Thakur ME, editors. The American Psychiatric Publishing Textbook of Geriatric Psychiatry, DSM-5 edition Arlington (TX: ): American Psychiatric Publishing; 2015. p. 527–587.
-
- Alexopoulos GS, Katz IR, Reynolds CF, et al. Pharmacotherapy of depression in older patients: a summary of the expert consensus guidelines. J Psychiatr Pract. 2001;7(6):361–376. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical